Search Medical Condition
Please enter condition
Please choose location

Liver Disorders Clinical Trials

A listing of Liver Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (66) clinical trials

Clinical Trials of Texas, Inc. is enrolling now for an investigational medication for patients with non-alcoholic fatty liver disease. Study participation is approximately 98 days. Qualified participants will receive study-related medical care from a board-certified physician, study medications, exams and evaluations. Qualified participants will help further medical science for treatment ...

Phase N/A

To study the investigational drug, obeticholic acid (also known as OCA), and its effect on NASH and to find out how safe and effective OCA may be in delaying specific medical conditions or health related issues that can occur in patients with NASH and evidence of liver fibrosis. Patients will ...

Phase

People with nonalcoholic steatohepatitis are asked to participate in a research study being conducted by North Shore University Hospital, Northwell Health

Phase N/A

Wake Research Associates is currently enrolling volunteers in a research study of the safety and effectiveness of an investigational drug for excess fat in the liver (NASH*).

Phase

A study of an investigational treatment in patients with anal fissures. REF: x41

Phase

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Study Evaluating the Safety and Efficacy of Obeticholic Acid (study medication) in Subjects with Nonalcoholic Steatohepatitis (NASH).

Phase

A Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 (Study Medication) compared to Placebo in Subjects with Chronic Pancreatitis.

Phase N/A

Nonalcoholic steatohepatitis (NASH) is an advanced form of fatty liver disease. It is caused by excess fat in the liver that leads to inflammation and tissue injury. People with type 2 diabetes, obesity, high cholesterol, insulin resistance, and high blood pressure may have NASH. ACRC Trials is conducting a research ...

Phase

The primary objective of this study is to evaluate whether SEL can cause fibrosis regression and reduce progression to cirrhosis and associated complications in subjects with NASH and bridging (F3) fibrosis. The secondary objective of this study is to assess the safety and tolerability of SEL in subjects with NASH ...

Phase N/A